A retrospective 15-year review: Survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 4, 2015, Pages 379-392

  Shah, M ^a   Shankar, A ^a   Gee, I ^b   Nash, K ^a   Hoare, M ^a,c   Gibbs, P ^d   Davies, S ^d   Alexander, G J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; MESSENGER RNA; METHYLPREDNISOLONE; PEGINTERFERON; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACNE; ADULT; ARTICLE; CAUSE OF DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; END STAGE RENAL DISEASE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HEPATIC ARTERY THROMBOSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MOUTH ULCER; NEPHROTIC SYNDROME; PERIPHERAL EDEMA; PNEUMONIA; PROTEINURIA; RASH; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT INDICATION; TUBERCULOSIS; AGED; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; COMORBIDITY; HEPACIVIRUS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES;

ADULT; AGED; CALCINEURIN INHIBITORS; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 84921433405     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13049     Document Type: Article

References (81)

1. Berenguer M, Prieto M, Rayon JM, et al,. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 Pt 1): 852-8.
2. Gane EJ, Portmann BC, Naoumov NV, et al,. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-20.
3. Thuluvath PJ, Krok KL, Segev DL, Yoo HY,. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007; 13: 719-24.
4. Berenguer M, Prieto M, San Juan F, et al,. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
5. Samuel D, Forns X, Berenguer M, et al,. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45: 127-43.
6. Yilmaz N, Shiffman ML, Stravitz RT, et al,. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975-83.
7. Berenguer M, Ferrell L, Watson J, et al,. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84.
8. Roche B, Samuel D,. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepatitis 2007; 14 (Suppl. 1): 89-96.
9. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87.
10. Berenguer M,. Treatment of hepatitis C after liver transplantation. Clin Liver Dis 2005; 9: 579-600, vi.
11. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
12. Magy N, Cribier B, Schmitt C, et al,. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999; 21: 253-61.
13. Sgourakis G, Radtke A, Fouzas I, et al,. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22: 892-905.
14. Klintmalm GB, Davis GL, Teperman L, et al,. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394-403.
15. Vivarelli M, Burra P, La Barba G, et al,. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007; 47: 793-8.
16. Berenguer M, Aguilera V, San Juan F, et al,. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204-9.
17. Fernandes F, Ansari IU, Striker R,. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS ONE 2010; 5: e9815.
18. Cescon M, Grazi GL, Cucchetti A, et al,. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-9.
19. Chang GJ, Mahanty HD, Quan D, et al,. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000; 6: 734-40.
20. Trotter JF,. Sirolimus in liver transplantation. Transplant Proc 2003; 35 (3 Suppl.): 193S-200S.
21. Watson CJ, Friend PJ, Jamieson NV, et al,. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505-9.
22. Wiesner RH, Sorrell M, Villamil F,. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9.
23. FDA. Information for Healthcare Professionals: Sirolimus (marketed as Rapamune) U.S Food and Drug Administration: U.S Food and Drug Administration, 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165015.htm (accessed 23/08/2014).
24. Asrani SK, Wiesner RH, Trotter JF, et al,. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant 2014; 14: 356-66.
25. Kneteman NM, Oberholzer J, Al Saghier M, et al,. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-11.
26. Cotterell AH, Fisher RA, King AL, et al,. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16 (Suppl. 7): 49-51.
27. Morard I, Dumortier J, Spahr L, et al,. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13: 658-64.
28. Di Benedetto F, Di Sandro S, De Ruvo N, et al,. Immunosuppressive switch to sirolimus in renal dysfunction after liver transplantation. Transplant Proc 2009; 41: 1297-9.
29. Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P,. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation 2011; 91: 128-32.
30. Asrani SK, Leise MD, West CP, et al,. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 2010; 52: 1360-70.
31. Morelon E, Kreis H,. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35 (3 Suppl.): 52S-7S.
32. Boratynska M, Banasik M, Watorek E, et al,. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006; 38: 101-4.
33. Harrison DE, Strong R, Sharp ZD, et al,. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-5.
34. Wilkinson JE, Burmeister L, Brooks SV, et al,. Rapamycin slows aging in mice. Aging Cell 2012; 11: 675-82.
35. Sharp ZD, Bartke A,. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J Gerontol A Biol Sci Med Sci 2005; 60: 293-300.
36. Shegogue D, Trojanowska M,. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004; 279: 23166-75.
37. Bonegio RG, Fuhro R, Wang Z, et al,. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-72.
38. Hattori N, Degen JL, Sisson TH, et al,. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106: 1341-50.
39. Poulalhon N, Farge D, Roos N, et al,. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent? J Biol Chem 2006; 281: 33045-52.
40. Patsenker E, Schneider V, Ledermann M, et al,. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55: 388-98.
41. Asthana S, Toso C, Meeberg G, et al,. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011; 25: 28-34.
42. McKenna GJ, Trotter JF, Klintmalm E, et al,. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-87.
43. Neuberger J, Gimson A, Davies M, et al,. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008; 57: 252-7.
44. Colloredo G, Guido M, Sonzogni A, Leandro G,. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-244.
45. Wagner D, Kniepeiss D, Schaffellner S, et al,. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol 2010; 10: 990-3.
46. Teperman L, Moonka D, Sebastian A, et al,. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013; 19: 675-89.
47. Trotter JF, Wachs M, Bak T, et al,. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343-51.
48. Watt KD, Dierkhising R, Heimbach JK, Charlton MR,. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012; 18: 1029-36.
49. Abdelmalek MF, Humar A, Stickel F, et al,. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12: 694-705.
50. Neff GW, Montalbano M, Tzakis AG,. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003; 35 (3 Suppl.): 209S-16S.
51. Dunkelberg JC, Trotter JF, Wachs M, et al,. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003; 9: 463-8.
52. McAlister VC, Peltekian KM, Malatjalian DA, et al,. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701-8.
53. Zimmerman MA, Trotter JF, Wachs M, et al,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-8.
54. Campbell MS, Rai J, Kozin E, et al,. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant 2007; 21: 377-84.
55. Toso C, Meeberg GA, Bigam DL, et al,. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162-8.
56. Chinnakotla S, Davis GL, Vasani S, et al,. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-42.
57. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-43.
58. Liang W, Wang D, Ling X, et al,. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18: 62-9.
59. Kelly MA, Kaplan M, Nydam T, et al,. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc 2013; 45: 3325-8.
60. Younossi ZM, Stepanova M, Saab S, et al,. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther 2014; 40: 686-94.
61. Marchetti P, Navalesi R,. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23: 482-90.
62. Johnston O, Rose CL, Webster AC, Gill JS,. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-8.
63. McKenna GJ, Trotter JF, Klintmalm E, et al,. Sirolimus and cardiovascular disease risk in liver transplantation. Transplantation 2013; 95: 215-21.
64. Uhlmann D, Weber T, Ludwig S, et al,. Long-term outcome of conversion to sirolimus monotherapy after liver transplant. Exp Clin Transplant 2012; 10: 30-8.
65. Watson CJ, Gimson AE, Alexander GJ, et al,. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694-702.
66. Fisher A, Seguel JM, de la Torre AN, et al,. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl 2004; 10: 193-8.
67. Arjal RR, Burton JR Jr, Villamil F, Rosen HR,. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007; 26: 127-40.
68. Guillouche P, Feray C,. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163-74.
69. Miller MH, Agarwal K, Austin A, et al,. Review article: 2014 UK consensus guidelines-hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014; 39: 1363-75.
70. Koff RS,. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-87.
71. Martel RR, Klicius J, Galet S,. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55: 48-51.
72. Kay JE, Kromwel L, Doe SE, Denyer M,. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991; 72: 544-9.
73. Miller RA, Harrison DE, Astle CM, et al,. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66: 191-201.
74. Anisimov VN, Zabezhinski MA, Popovich IG, et al,. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010; 176: 2092-7.
75. Anisimov VN, Zabezhinski MA, Popovich IG, et al,. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011; 10: 4230-6.
76. Singh R, Kaushik S, Wang Y, et al,. Autophagy regulates lipid metabolism. Nature 2009; 458: 1131-5.
77. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al,. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57: 945-57.
78. Teutonico A, Schena PF, Di Paolo S,. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-35.
79. Lewis GF, Carpentier A, Adeli K, Giacca A,. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29.
80. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT,. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999; 55: 2407-14.
81. Canaud G, Bienaime F, Viau A, et al,. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med 2013; 19: 1288-96.